M
Mosaic Therapeutics
Oncology combination therapies for biomarker-defined patient populations
About Mosaic Therapeutics
Mosaic Therapeutics is a clinical-stage oncology therapeutics company that discovers and develops targeted drug combinations for biomarker-defined patient groups. The company was spun out of the Wellcome Sanger Institute in 2020 and is built on over 15 years of its research in collaboration with the Netherlands Cancer Institute.
The company was co-founded by Dr. Mathew Garnett, Professor Emile Voest, and Dr. Adrian Ibrahim. Garnett is a senior group leader at the Sanger Institute with extensive experience in genomics and cancer therapeutics, including the co-discovery of BRAF mutations in cancer. Voest is a Professor of Medical Oncology and Chairman of the Board of Cancer Core Europe. Ibrahim was formerly the Head of Technology Translation at the Wellcome Sanger Institute.
Mosaic's platform integrates computational biology, large-scale cancer model screening, and big data analysis to identify synergistic drug combinations and the predictive biomarkers associated with a response. This approach aims to deliver more effective and less toxic therapies by moving away from a 'one-size-fits-all' treatment model. The company utilizes advanced cancer models, including patient-derived organoids, and employs genome-scale CRISPR and drug screening to test potential therapeutic options.
In April 2023, Mosaic Therapeutics closed a $28 million Series A funding round from Syncona Investment Management and Cambridge Innovation Capital. This funding was intended to advance its pipeline through preclinical development and expand its scientific and leadership teams. In April 2025, the company transitioned to a clinical-stage business by in-licensing two clinical-stage oncology programs from Astex Pharmaceuticals: ASTX029, an ERK1/2 inhibitor, and ASTX295, an MDM2 antagonist. This deal, which gave Astex an equity stake in Mosaic, is set to accelerate the development of proprietary combination therapies, with the first clinical study expected to commence in 2026.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Cambridge, United Kingdom
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 64.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Precision Medicine, Spinout, Hard Tech, DT and LS, uk is8 life sciences, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Apr 2025 | $14M | $140M | Undisclosed | ↗ |
| SERIES A✓Equity / VC | Apr 2023 | $28M | $112M | Syncona · Cambridge Innovation Capital | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Mosaic Therapeutics is 540 monthly website visits, down 6.9% over the last three months. Mosaic Therapeutics's team declined 23.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Mosaic Therapeutics in the Cambridge ecosystem
The Mosaic Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Syncona
Cambridge Innovation Capital
Other known investors1 additional known investor
Wellcome Trust Sanger Institute
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mosaic Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mosaic Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









